Scott Stoffel News
-
An Abbott Laboratories stockholder suit accusing directors of shirking their duty to supervise the marketing of its epilepsy drug Depakote can go forward, a federal judge ruled.
-
Abbott Laboratories agreed to pay at least $1.3 billion to settle claims by the U.S. government and 24 states alleging the company illegally marketed its Depakote epilepsy drug, people familiar with the accords said.
-
Abbott Laboratories , maker of the rheumatoid arthritis treatment Humira, agreed to license at least 24 generic medicines from Cadila Healthcare Ltd. and begin selling them in emerging markets.
-
Swiss banks will likely settle a sweeping U.S. probe of offshore tax evasion by paying billions of dollars and handing over names of thousands of Americans who have secret accounts, Bloomberg News’ David Voreacos, Klaus Wille and Giles Broom report.
-
Abbott Laboratories was refused patent protection on its AIDS drug Kaletra by India’s patent office, allowing Cipla Ltd. and other generic-drug companies to continue selling copies.
-
Johnson & Johnson, the world’s biggest maker of health-care products, may sell its $2.2 billion diagnostics unit for blood and cholesterol tests as the company focuses on genetic screening to complement its drug pipeline.
-
Impax Laboratories Inc. said it settled patent litigation with Abbott Laboratories and its Fournier Laboratories Ireland Ltd. unit, permitting Impax to sell a generic version of the cholesterol drug TriLipix as early as 2013.
-
Facebook Inc. and its co-founder Mark Zuckerberg asked a court to order Paul Ceglia, the New York man who claims half of Zuckerberg’s holdings, to turn over the original contract and e-mails on which he bases his suit, saying the steps are needed to short-circuit a fraud on the court.
-
ITT Corp ., a military electronics supplier, said it reached a settlement of patent-infringement claims it filed against Motorola Inc. over assisted-global position system technology.
-
Abbott Laboratories , the maker of the arthritis drug Humira, succeeded in a bid to overturn a $1.67 billion patent-infringement verdict won by Johnson & Johnson .
|
|
Most Popular on Bloomberg
|
| |
Rate this Page